CO6351782A2 - COMPUESTOS NOVEDOSOS CON ACTIVIDAD ANTAGONISTA DEL RECEPTOR á 7 NICOTINICO DE ACETILCOLINA - Google Patents

COMPUESTOS NOVEDOSOS CON ACTIVIDAD ANTAGONISTA DEL RECEPTOR á 7 NICOTINICO DE ACETILCOLINA

Info

Publication number
CO6351782A2
CO6351782A2 CO09070527A CO09070527A CO6351782A2 CO 6351782 A2 CO6351782 A2 CO 6351782A2 CO 09070527 A CO09070527 A CO 09070527A CO 09070527 A CO09070527 A CO 09070527A CO 6351782 A2 CO6351782 A2 CO 6351782A2
Authority
CO
Colombia
Prior art keywords
nicotinico
acetilcolina
new compounds
antagonist activity
receiver antagonist
Prior art date
Application number
CO09070527A
Other languages
English (en)
Spanish (es)
Inventor
Chiara Ghiron
Arianna Nencini
Boyd Harrison
Simon Haydar
Carmela Pratelli
Maurizio Varrone
Hendrick Bothmann
Laura Maccari
Riccardo Zanaletti
Iolanda Micco
Original Assignee
Siena Biotech Spa
Wyeth Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siena Biotech Spa, Wyeth Pharmaceuticals filed Critical Siena Biotech Spa
Publication of CO6351782A2 publication Critical patent/CO6351782A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
CO09070527A 2007-01-16 2009-07-08 COMPUESTOS NOVEDOSOS CON ACTIVIDAD ANTAGONISTA DEL RECEPTOR á 7 NICOTINICO DE ACETILCOLINA CO6351782A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88062907P 2007-01-16 2007-01-16

Publications (1)

Publication Number Publication Date
CO6351782A2 true CO6351782A2 (es) 2011-12-20

Family

ID=39345157

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09070527A CO6351782A2 (es) 2007-01-16 2009-07-08 COMPUESTOS NOVEDOSOS CON ACTIVIDAD ANTAGONISTA DEL RECEPTOR á 7 NICOTINICO DE ACETILCOLINA

Country Status (25)

Country Link
US (1) US8163729B2 (US08163729-20120424-C00275.png)
EP (1) EP2118067B1 (US08163729-20120424-C00275.png)
JP (1) JP2010515770A (US08163729-20120424-C00275.png)
KR (1) KR20090116707A (US08163729-20120424-C00275.png)
CN (1) CN101679287B (US08163729-20120424-C00275.png)
AR (1) AR064921A1 (US08163729-20120424-C00275.png)
AU (1) AU2008206759B2 (US08163729-20120424-C00275.png)
BR (1) BRPI0806665A2 (US08163729-20120424-C00275.png)
CA (1) CA2675676A1 (US08163729-20120424-C00275.png)
CL (1) CL2008000119A1 (US08163729-20120424-C00275.png)
CO (1) CO6351782A2 (US08163729-20120424-C00275.png)
CR (1) CR10930A (US08163729-20120424-C00275.png)
EA (1) EA016948B1 (US08163729-20120424-C00275.png)
EC (1) ECSP099490A (US08163729-20120424-C00275.png)
HK (1) HK1142335A1 (US08163729-20120424-C00275.png)
IL (1) IL199889A0 (US08163729-20120424-C00275.png)
MX (1) MX2009007615A (US08163729-20120424-C00275.png)
NZ (1) NZ578411A (US08163729-20120424-C00275.png)
PA (1) PA8766201A1 (US08163729-20120424-C00275.png)
SA (1) SA08290018B1 (US08163729-20120424-C00275.png)
SV (1) SV2009003334A (US08163729-20120424-C00275.png)
TW (1) TW200901974A (US08163729-20120424-C00275.png)
UA (1) UA98317C2 (US08163729-20120424-C00275.png)
WO (1) WO2008087529A1 (US08163729-20120424-C00275.png)
ZA (1) ZA200904943B (US08163729-20120424-C00275.png)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
US20090264648A1 (en) * 2008-01-14 2009-10-22 Wyeth Synthesis of pyrazoles
WO2009091831A1 (en) * 2008-01-14 2009-07-23 Wyeth Compound forms and uses thereof
WO2009091813A1 (en) * 2008-01-14 2009-07-23 Wyeth Compounds useful as alpha7 nicotinic acetylcholine receptor agonists
TW201004941A (en) * 2008-07-16 2010-02-01 Wyeth Corp Alpha7 nicotinic acetylcholine receptor inhibitors
US8653131B2 (en) 2008-08-22 2014-02-18 Baxter Healthcare S.A. Polymeric benzyl carbonate-derivatives
WO2010104843A2 (en) * 2009-03-09 2010-09-16 The Regents Of The University Of California Substituted heterocycles and their use as allosteric modulators of nicotinic and gabaa receptors
CN102573842A (zh) * 2009-07-23 2012-07-11 诺瓦提斯公司 氮杂双环烷基衍生物或吡咯烷-2-酮衍生物的用途
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
UA113501C2 (uk) 2010-11-03 2017-02-10 Пестицидні композиції і пов'язані з ними способи
CA2813451A1 (en) * 2010-11-18 2012-05-24 Dignity Health Methods of diagnosing and treating neurodegenerative diseases
WO2014054635A1 (ja) * 2012-10-02 2014-04-10 大日本住友製薬株式会社 イミダゾール誘導体
CN105254564A (zh) * 2015-10-31 2016-01-20 丁玉琴 一种2-甲基-3,4-二硝基-5-(甲氧苯基)吡唑的合成方法
CN105646358B (zh) * 2016-03-01 2018-03-09 苏州艾缇克药物化学有限公司 一种3‑氨基‑5‑(4‑甲氧苯基)吡唑的合成方法
CN112457255B (zh) * 2017-11-08 2022-08-19 北京嘉林药业股份有限公司 化合物及其治疗癌症的用途
TWI805699B (zh) 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
WO2019194207A1 (ja) 2018-04-04 2019-10-10 日本たばこ産業株式会社 ヘテロアリールで置換されたピラゾール化合物及びその医薬用途
GB202006382D0 (en) 2020-04-30 2020-06-17 Spermatech As Use
CN113925606B (zh) * 2021-10-25 2023-07-07 四川大学华西医院 一种神经调控导航定位方法、装置和神经调控治疗系统

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU167263B (US08163729-20120424-C00275.png) * 1973-02-12 1975-09-27
DE2527677A1 (de) * 1975-06-21 1977-01-20 Bayer Ag Verfahren zur herstellung von 2,4- dioxo-1,2,3,4-tetrahydro-s-triazino- eckige klammer auf 1,2-a eckige klammer zu -benzimidazolen
US4624954A (en) * 1985-12-20 1986-11-25 American Home Products Corporation 6,7,8,9-tetrahydro-10-methylpyrido[1,2-a]indol-9-amines and derivatives thereof, useful for the treatment of cognitive impairments
US4665183A (en) 1985-12-20 1987-05-12 American Home Products Corp. Process for preparing 6,7,8,9-tetrahydro-10-methylpyrido[1,2-a]indol-9-amines and derivatives thereof useful for the treatment of cognitive impairments
US5219857A (en) 1986-10-16 1993-06-15 American Cyanamid Company Method of treating cognitive and related neural behavioral problems
US4904658A (en) * 1988-04-15 1990-02-27 American Cyanamid Company Substituted-6H,8H-pyrimido-[1,2,3-cd]purine-8,10-(9H)-diones and substituted-6H,10H-pyrimido[1,2-cd]purin-10-ones
US5260331A (en) 1989-01-02 1993-11-09 John Wyeth & Brother Limited Composition for treating depression with (S- or O-heteroaryl)alkyl amines
US5422355A (en) * 1989-06-02 1995-06-06 John Wyeth & Brother, Limited Composition for treating depression with (N-heteroaryl)alkylamines
FR2655988B1 (fr) * 1989-12-20 1994-05-20 Adir Cie Nouveaux derives de la napht-1-yl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
IE911774A1 (en) 1990-06-11 1991-12-18 Akzo Nv Pyridinylpiperazine derivatives
IL101722A (en) 1991-05-02 1996-05-14 Wyeth John & Brother Ltd History of piperazine, their preparation and pharmaceutical preparations containing them
GB9125615D0 (en) 1991-12-02 1992-01-29 Wyeth John & Brother Ltd Amines
WO1993013083A1 (en) 1991-12-31 1993-07-08 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
JPH0616638A (ja) 1992-03-30 1994-01-25 Yoshitomi Pharmaceut Ind Ltd ピリジン化合物およびその医薬用途
PT1156043E (pt) 1992-07-24 2004-03-31 Univ California Drogas que aumentam as respostas sinapticas mediadas por receptores de ampa
KR0170567B1 (ko) 1992-12-17 1999-02-18 알렌 제이. 스피겔 부신피질자극호르몬-유리 인자 길항물질 활성을 갖는 피라졸 및 피라졸로피리미딘
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
DK0674631T3 (da) 1992-12-17 2000-04-10 Pfizer Substituerede pyrazoler som CRF-antogonister
TW444018B (en) 1992-12-17 2001-07-01 Pfizer Pyrazolopyrimidines
RU2124015C1 (ru) 1992-12-17 1998-12-27 Пфайзер Инк. Производные пирроло [2,3-d] пиримидинов, фармацевтическая композиция, пирроло [2,3-d] пиримидины, производные пиррола
GB9302622D0 (en) 1993-02-10 1993-03-24 Wellcome Found Heteroaromatic compounds
KR100327270B1 (ko) 1994-01-14 2002-08-01 닛뽕쇼지가부시끼가이샤 디아자시클로알킨알킬술폰아미드유도체
JP3319651B2 (ja) * 1994-04-26 2002-09-03 富士写真フイルム株式会社 感光性転写シート
US5650409A (en) 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
GB9514901D0 (en) 1995-07-20 1995-09-20 American Home Prod Piperazine derivatives
US6288091B1 (en) * 1995-12-29 2001-09-11 Boehringer Ingelheim Ltd. Antiherpes virus compounds and methods for their preparation and use
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5736543A (en) 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
ATE232850T1 (de) 1996-05-11 2003-03-15 Smithkline Beecham Plc Tetrahydroisoquinoline derivate als modulatoren von dopamine d3 rezeptoren
GB9708694D0 (en) 1997-04-30 1997-06-18 Smithkline Beecham Plc Compounds
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
US6329368B1 (en) 1997-05-09 2001-12-11 The Regents Of The University Of California Endocrine modulation with positive modulators of AMPA type glutamate receptors
KR100247563B1 (ko) 1997-07-16 2000-04-01 박영구 키랄3,4-에폭시부티르산및이의염의제조방법
WO1999005140A1 (en) * 1997-07-25 1999-02-04 H. Lundbeck A/S Indole and 2,3-dihydroindole derivatives, their preparation and use
US6632823B1 (en) 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
CA2320354A1 (en) 1998-02-18 1999-08-26 Neurosearch A/S Novel compounds and their use as positive ampa receptor modulators
CA2326804C (en) 1998-03-31 2006-05-02 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
US6124278A (en) 1998-04-03 2000-09-26 The Regents Of The University Of California Acylbenzoxazines for enhancing synaptic response
ATE255888T1 (de) 1998-06-01 2003-12-15 Ortho Mcneil Pharm Inc Tetrahydronaphtalene verbindungen und deren verwendung zur behandlung von neurodegenerativen krankheiten
US6605623B1 (en) 1998-12-18 2003-08-12 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6313126B1 (en) 1999-01-07 2001-11-06 American Home Products Corp Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
KR20010101675A (ko) 1999-01-26 2001-11-14 우에노 도시오 2ｈ-프탈라진-1-온 유도체 및 그 유도체를 유효 성분으로하는 약제
US20010044445A1 (en) * 1999-04-08 2001-11-22 Bamaung Nwe Y. Azole inhibitors of cytokine production
US6387900B1 (en) 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
WO2001032604A1 (en) 1999-11-05 2001-05-10 University College London Activators of soluble guanylate cyclase
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
JP2003521543A (ja) * 2000-02-07 2003-07-15 アボット ゲーエムベーハー ウント カンパニー カーゲー ２−ベンゾチアゾリル尿素誘導体およびそのプロテインキナーゼ阻害剤としての使用
ES2286114T3 (es) 2000-03-31 2007-12-01 Ortho-Mcneil Pharmaceutical, Inc. Imidazopiridina fenil-substituidos.
ES2325477T3 (es) 2000-03-31 2009-09-07 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indoles sustituidos por fenilo como antagonistas del receptor de histamina h3.
YU73902A (sh) 2000-04-10 2005-09-19 Pfizer Products Inc. Jedinjenja koja sadrže benzoamid-piperidin i srodna jedinjenja
US6448276B1 (en) 2000-05-17 2002-09-10 Inspire Pharmaceuticals, Inc. Method for treating vaginal dryness with nicotinic acetylcholine receptor agonists
CA2413418A1 (en) 2000-06-21 2001-12-27 Joseph B. Santella Piperidine amides as modulators of chemokine receptor activity
JP2002030073A (ja) 2000-07-19 2002-01-29 Ono Pharmaceut Co Ltd ４−（３−（４−モルホリノブチリルアミノ）フェニル）−２ｈ−フタラジン−１−オン・メタンスルホン酸塩・１水和物およびその製造方法。
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US20020173507A1 (en) 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
IL145209A0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
AU2001287898A1 (en) 2000-09-22 2002-04-02 Stephen Garland Pyrazolopyridines and pyrazolopyridazines as antidiabetics
US6469007B2 (en) * 2000-11-28 2002-10-22 Wyeth Serotonergic agents
CN1263750C (zh) 2000-12-13 2006-07-12 惠氏 β淀粉样蛋白产生的杂环磺酰胺类抑制剂
UA73619C2 (en) 2000-12-13 2005-08-15 Pfizer Prod Inc Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
DK1362039T3 (da) 2001-02-16 2006-05-08 Aventis Pharma Inc Heterocykliske, substituerede carbonylderivater og deres anvendelse som dopamin D3-receptorligander
WO2002066468A2 (en) 2001-02-16 2002-08-29 Aventis Pharmaceuticals Inc. Heterocyclic urea derivatives and their use as dopamine d3 receptor ligands
HUP0103987A3 (en) 2001-09-28 2004-11-29 Richter Gedeon Vegyeszet Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
HUP0103986A2 (hu) 2001-09-28 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Új karbonsavamid szerkezetet tartalmazó piperidinil vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
KR100579813B1 (ko) 2001-10-16 2006-05-12 주식회사 에스티씨나라 피페리딘 유도체, 이의 제조방법 및 이를 포함하는 치매치료용 약학적 조성물
WO2003070707A1 (fr) * 2002-02-19 2003-08-28 Ono Pharmaceutical Co., Ltd. Composes condenses derives de la pyridazine et medicaments contenant lesdits composes comme ingredients actifs
DE10211415A1 (de) * 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
UA77814C2 (en) 2002-07-03 2007-01-15 Lundbeck & Co As H Spirocyclic piperidines as antagonists of mch1 and use thereof
US7183411B2 (en) * 2002-07-12 2007-02-27 Janssen Pharmaceutica N.V. Naphthol, quinoline and isoquinoline-derived urea modulators of vanilloid VR1 receptor
GB0216233D0 (en) 2002-07-12 2002-08-21 Glaxo Group Ltd Compounds
TW200401641A (en) * 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
AU2003253686A1 (en) 2002-08-01 2004-02-23 Pharmacia & Upjohn Company Llc 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
WO2004039366A1 (en) 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
US7157460B2 (en) * 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7186832B2 (en) * 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
TWI334868B (en) * 2003-06-03 2010-12-21 Nippon Kayaku Kk [1,2,4] triazoro [1,5-a] pyrimidine-2-ylurea derivative and use thereof
PL1648904T3 (pl) * 2003-07-31 2008-01-31 Wyeth Corp Związki N-sulfonyloheterocyklopirolioalkiloaminowe jako ligandy 5-hydroksytryptaminy-6
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1713809B1 (en) 2004-02-04 2009-07-29 Neurosearch A/S Dimeric azacyclic compounds and their use
CA2556622A1 (en) * 2004-03-02 2005-09-15 Wyeth Macrolides and methods for producing same
EP1720548A1 (en) * 2004-03-02 2006-11-15 Wyeth Non-immunosuppressive immunophilin ligands as neuroprotective and/or neuroregenerative agents
WO2006009655A1 (en) * 2004-06-16 2006-01-26 Wyeth Diphenylimidazopyrimidine and -imidazole amines as inhibitors of b-secretase
EP1756087B1 (en) 2004-06-16 2009-10-07 Wyeth Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase
BRPI0511993A (pt) * 2004-07-20 2008-01-22 Siena Biotech Spa compostos moduladores de receptores de acetilcolina nicotìnicos alfa7, composições farmacêuticas e usos terapêuticos dos mesmos
EP1778652A2 (en) 2004-08-20 2007-05-02 EntreMed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
WO2006077428A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Pharmaceutical compounds
WO2006091858A1 (en) 2005-02-25 2006-08-31 Rigel Pharmaceuticals, Inc. Benzisothiazoles useful for treating or preventing hcv infection
US20090181852A1 (en) * 2005-11-15 2009-07-16 Inverness Medical Switerland Gmbh Assays
CA2637530A1 (en) 2006-01-18 2007-09-07 Siena Biotech S.P.A. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
GB0723815D0 (en) 2007-12-05 2008-01-16 Glaxo Group Ltd Compounds
WO2009091831A1 (en) 2008-01-14 2009-07-23 Wyeth Compound forms and uses thereof
US20090264648A1 (en) * 2008-01-14 2009-10-22 Wyeth Synthesis of pyrazoles
WO2009091813A1 (en) 2008-01-14 2009-07-23 Wyeth Compounds useful as alpha7 nicotinic acetylcholine receptor agonists
TW201004941A (en) 2008-07-16 2010-02-01 Wyeth Corp Alpha7 nicotinic acetylcholine receptor inhibitors
US20100016598A1 (en) * 2008-07-16 2010-01-21 Wyeth Alpha7 nicotinic acetylcholine receptor inhibitors
US20100016360A1 (en) * 2008-07-16 2010-01-21 Wyeth Alpha7 nicotinic acetylcholine receptor inhibitors
US20100016343A1 (en) * 2008-07-16 2010-01-21 Wyeth Alpha7 nicotinic acetylcholine receptor inhibitors

Also Published As

Publication number Publication date
EP2118067A1 (en) 2009-11-18
AU2008206759A1 (en) 2008-07-24
CN101679287A (zh) 2010-03-24
HK1142335A1 (en) 2010-12-03
BRPI0806665A2 (pt) 2011-09-06
PA8766201A1 (es) 2008-11-19
IL199889A0 (en) 2010-04-15
ECSP099490A (es) 2009-09-29
NZ578411A (en) 2011-06-30
US20100029606A1 (en) 2010-02-04
SV2009003334A (es) 2010-08-09
US8163729B2 (en) 2012-04-24
ZA200904943B (en) 2010-09-29
UA98317C2 (ru) 2012-05-10
CL2008000119A1 (es) 2008-05-16
CR10930A (es) 2013-02-12
AU2008206759B2 (en) 2013-09-05
SA08290018B1 (ar) 2013-01-17
CN101679287B (zh) 2013-03-27
EA200900831A1 (ru) 2010-02-26
CA2675676A1 (en) 2008-07-24
KR20090116707A (ko) 2009-11-11
TW200901974A (en) 2009-01-16
EA016948B1 (ru) 2012-08-30
AR064921A1 (es) 2009-05-06
EP2118067B1 (en) 2013-05-08
MX2009007615A (es) 2009-07-27
JP2010515770A (ja) 2010-05-13
WO2008087529A1 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
CO6351782A2 (es) COMPUESTOS NOVEDOSOS CON ACTIVIDAD ANTAGONISTA DEL RECEPTOR á 7 NICOTINICO DE ACETILCOLINA
ECSP10010390A (es) Compuestos
SV2005002061A (es) Derivados de piridilo y su uso como antagonistas del receptor mglu5 ref. x-16538
ECSP12012326A (es) Derivados de aminopirimidina como moduladores de la lrrk2
PE20150891A1 (es) Anticuerpos anti-receptor de il-13 alfa 2 y conjugados de anticuerpo farmaco
CL2012003604A1 (es) Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
ZA201100526B (en) Triazolo [4,5-d]pyramidine derivatives and their use as purine receptor antagonists
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
ECSP067116A (es) Antagonistas del receptor 2 de citocina quimioatrayente de sales cuaternarias
PA8795601A1 (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
GT200600081A (es) Derivados de acetilenno
CL2009000697A1 (es) Compuestos derivados de 2-heteroaril-6-fenil-imidazol [1,2-a]piridinas sustituidas; moduladores de receptores not; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de cancer, inflamacion, enfermedades neurodegenerativas, psiquiatricas, epilepsia, entre otras.
BR112012013431A2 (pt) composto, composição farmacêutica e seu uso
CO6361994A2 (es) Antagonistas del receptor de orexina de isonicotinamida
CO6300941A2 (es) Compuestos de quinuclidina como ligandos del receptor nicotinico de acetilcolina alfa 7
EA201071291A3 (ru) Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств
CL2008001636A1 (es) Compuestos derivados de bencimidazol, antagonistas de los receptores de angiotensina ii de tipo 1; proceso de preparacion de dichos compuestos; compuestos intermediarios; composicion farmaceutica de los compuestos; y su uso para tratar la hipertension, insuficiencia cardiaca.
AR063158A1 (es) Asenapina amorfa,p rocesos para prepararla, composiciones farmaceuticas solidas que la contienen y su uso para tratar trastornos del sistema nervioso central.
CY1120403T1 (el) Ανταγωνιστες trpm8
CL2008001658A1 (es) Composicion farmaceutica que comprende mesilato de imatinib amorfo y un principio de formulacion que estabiliza la forma amorfa; y su uso para tratar leucemia mieloide cronica avanzada y recientemente diagnosticada, leucemia mielomonocitica cronica, glioblastoma multiforme, entre otras.
ECSP099675A (es) Compuestos heterocíclicos, composición y métodos de uso
PA8795701A1 (es) Derivados de isoquinolinilo e isoindolinilo como antagonistas de histamina-3
ECSP088366A (es) 1,2-diarilimidazoles para uso como moduladores de cb1
ECSP11010956A (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos
ECSP088250A (es) Derivados de pirazol como agentes terapéuticos

Legal Events

Date Code Title Description
FA Application withdrawn